Neurogene Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Neurogene Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $67.00K.
- Neurogene Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $4.00K, a 93.65% decline year-over-year.
- Neurogene Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2022-06-30 was $63.00K, a 71.23% decline year-over-year.
- Neurogene Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2021-06-30 was $219.00K.
- Neurogene Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $84.00K.
- Neurogene Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $82.00K, a 77.96% decline from fiscal 2021.
- Neurogene Inc. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $372.00K, a 86.93% increase from fiscal 2020.
- Neurogene Inc. stock issued during period, value, employee stock purchase plan for fiscal 2020 was $199.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $67.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $84.00K 10-K · filed 2026-03-24 | |
| 2023-06-30 | $4.00K 10-Q · filed 2023-11-14 | |
| 2022-12-31 | $82.00K 10-K · filed 2023-03-20 | |
| 2022-06-30 | $63.00K 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $372.00K 10-K · filed 2023-03-20 | |
| 2021-06-30 | $219.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $199.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |